- Design
- Nationwide claims cohort with propensity overlap weighting and landmark analysis
- Population
- 14,355 adults in Japan with acute ischaemic stroke and atrial fibrillation
- Primary outcome
- Hospitalisation for recurrent ischaemic stroke or systemic embolism
- Effect
- HR 0.56 (95% CI 0.32 to 0.97); 5-year incidence 8.0% vs 13.8%
Using a Japanese administrative database, researchers compared patients who started antiarrhythmic drugs, ablation or cardioversion within eight weeks of an ischaemic stroke with those who did not. Few received early rhythm control.
Early rhythm control was associated with a lower risk of recurrent stroke or embolism and lower mortality. Results held across different landmark times.
Patients selected for rhythm control are likely healthier, and weighting cannot fully remove that bias. The signal is consistent with EAST-AFNET 4, which enrolled patients with recent atrial fibrillation, but a stroke-specific randomised trial is needed.
- Five-year recurrent stroke or embolism was 8.0% with early rhythm control against 13.8% without.
- All-cause mortality was also lower (HR 0.72).
- Major bleeding was not significantly different.
- The cohort was old, median age 83, so selection of fitter patients for rhythm control is likely.
- Anticoagulation remains the main secondary prevention for cardioembolic stroke.
Why it matters
Rhythm control is rarely started after stroke; only 1.9% of this cohort received it, despite trial evidence for early rhythm control in atrial fibrillation generally.
Don't overread it
This is an observational claims analysis; the authors call it hypothesis-generating.
The statistics, in plain English
An HR of 0.56 with an interval from 0.32 to 0.97 only just excludes no effect, and the risk difference interval crosses zero. With 268 treated patients, the estimate is imprecise.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free